Barclays PLC Raises Stake in Royalty Pharma plc (NASDAQ:RPRX)

Barclays PLC grew its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 16.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 308,887 shares of the biopharmaceutical company's stock after buying an additional 43,339 shares during the period. Barclays PLC owned approximately 0.05% of Royalty Pharma worth $8,737,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of RPRX. Blue Trust Inc. increased its position in Royalty Pharma by 362.7% in the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 943 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Royalty Pharma by 32.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company's stock valued at $76,000 after acquiring an additional 655 shares in the last quarter. Transamerica Financial Advisors Inc. raised its position in shares of Royalty Pharma by 99.9% during the third quarter. Transamerica Financial Advisors Inc. now owns 3,459 shares of the biopharmaceutical company's stock worth $98,000 after purchasing an additional 1,729 shares during the period. iA Global Asset Management Inc. lifted its holdings in shares of Royalty Pharma by 274.7% in the 2nd quarter. iA Global Asset Management Inc. now owns 6,388 shares of the biopharmaceutical company's stock worth $168,000 after purchasing an additional 4,683 shares in the last quarter. Finally, Lake Street Advisors Group LLC bought a new position in shares of Royalty Pharma in the 3rd quarter worth $211,000. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Stock Performance

Shares of RPRX stock traded down $0.65 on Wednesday, hitting $24.47. 3,732,111 shares of the stock were exchanged, compared to its average volume of 2,664,242. The firm has a market capitalization of $14.42 billion, a PE ratio of 12.68, a P/E/G ratio of 4.36 and a beta of 0.46. Royalty Pharma plc has a one year low of $24.46 and a one year high of $31.66. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The firm's 50 day moving average is $26.61 and its two-hundred day moving average is $27.21.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th were issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.43%. The ex-dividend date of this dividend was Friday, November 15th. Royalty Pharma's payout ratio is 43.52%.

Analyst Ratings Changes

RPRX has been the subject of a number of recent research reports. StockNews.com raised Royalty Pharma from a "hold" rating to a "buy" rating in a report on Tuesday, November 5th. Citigroup decreased their price target on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating for the company in a report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Royalty Pharma currently has a consensus rating of "Moderate Buy" and a consensus price target of $41.67.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.